Medical strategy, built on the full picture.
We combine AI and human expertise to build a living evidence system for your disease. It maps the whole ecosystem, not just a handful of KOLs, country by country across Europe, and stays current as the evidence moves.
When functions work from different versions of the disease
In rare-disease programmes, medical, access and commercial teams often hold separate views of the evidence, the pathway and the priority markets. Decisions then rest on assumptions that no one has tested together.
We help you build one documented foundation that each function can inspect: what is established, where findings conflict, and how care pathways and stakeholder perspectives differ by market.
Three questions an engagement can answer
- 1
Who should we reach at each step of the patient journey, and when?
- 2
How do care pathways and centres of expertise differ across priority markets?
- 3
What stops or speeds adoption, market by market?
Start with the landscape. Go deeper where it matters.
Rare disease landscaping, country by country with a European lens. Usually 6 to 10 weeks to a first edition.
- Epidemiology
- Competitor activity
- Diagnosis, treatment and referral pathways
- KOLs and the specialists who matter
- Effectiveness of current products
- Country-specific patient journey
- Guidelines, and who writes them
- Stakeholders who influence decisions
New views on the same evidence layer
Contacts per journey step
Country-specific contacts for each step of the patient journey.
Quick pulse checks
Short interactions with tier 1 to 4 professionals.
Therapy and diagnostic watch list
Competing programmes and tests, tracked and sourced.
HTA evidence readiness
What payers will ask, and what is still missing.
Advisory board input
Open questions, and where experts disagree.
TPP simulation
Test profile options against the evidence and stakeholder views.
What you could receive
- Disease evidence and uncertainty register
- Country patient journey, with centres and care mapped by tier
- Care-pathway and stakeholder findings
- Prioritised questions for evidence planning
- Decision implications and agreed follow-up research
Proposed deliverables. Markets, stakeholder research and updates are agreed in scope.
Evidence and expert interpretation, kept distinct
AI-assisted mapping covers publications, trials, congresses, guidelines, registries and approvals. Every claim is linked to its source, with gaps and conflicting findings made explicit.
Interviews and surveys with specialists, from expertise centres to care close to home, show how the evidence plays out in each market. We report these views separately from the published evidence.
Our interpretation sets out what this means for your medical, access and launch plans, and is labelled as interpretation.
Where to start
Rare disease landscaping
The shared evidence and care-pathway baseline for the disease across priority markets.
Read moreBarrier and driver analysis
Uses that baseline to examine what blocks or supports adoption, market by market.
Read moreTPP validation
Tests profile assumptions against the evidence before trade-offs are locked.
Read moreRelated client results
Frequently asked questions
Will this secure reimbursement or uptake?
No outside work can guarantee that. We help you understand which assumptions are supported and what needs further investigation before you commit.
How are updates handled?
Updates are optional and agreed in scope, for example twice a year or when important developments arise. Not every engagement includes them.
Discuss your programme
Tell us the disease, the priority markets and the decision ahead. We will come back with what a scoped engagement would cover.